Volastra
Nicholas A. Saccomano, Ph.D., is an accomplished professional in the biotechnology and pharmaceutical sectors, currently serving as President and Chief Executive Officer at OnKure Therapeutics since October 2023. As an Independent Director/Advisor at Modulo Bio and BioLoomics, Inc., and an Advisor at Perceptive Advisors, Nicholas leverages extensive experience in scientific leadership positions, including Chief Scientific Officer and Senior Vice President roles at Pfizer, Array BioPharma, and SomaLogic. Nicholas's expertise encompasses strategic drug discovery and development, with significant contributions to precision medicines targeting cancer vulnerabilities. An educational background includes a Ph.D. in Organic Chemistry from Columbia University and a Bachelor of Science in Chemistry from the University at Buffalo.
This person is not in any teams
This person is not in any offices
Volastra
1 followers
Volastra Therapeutics, Inc., is developing novel therapies to treat and prevent the formation of metastatic disease. Launched from the laboratory of Dr. Lewis Cantley, along with Drs. Olivier Elemento and Samuel Bakhoum, Volastra has identified the mechanisms by which CIN drives the formation and proliferation of metastases. Following initial evidence that a patient’s CIN status is prognostic for metastasis and that CIN alters metastasis and overall survival in mouse models, the company is discovering mechanisms and pathways by which CIN modulates metastatic disease to develop novel therapeutics.